The inspector general, Anthony Zakel, found no proof that agency employees had any conflicts of interest in the deal and said he did not turn up "any evidence of misconduct on the part of DFC officials," according to a copy of the report obtained by The Wall Street Journal. The plan to fit out Kodak for active pharmaceutical ingredient (API) manufacturing was itself sound, Zakel said, citing other companies' recent efforts to shore up drug manufacturing stateside. The DFC had intended to establish capacity for the APIs in key generic drugs before its plan buckled under the weight of multiple investigations.